From the Departments of Pediatrics, National Cheng Kung University Hospital.
Pancreas. 2022 Apr 1;51(4):366-371. doi: 10.1097/MPA.0000000000002036. Epub 2022 Jun 12.
This study aimed to elucidate the characteristics and the risk factors for asparaginase-associated pancreatitis (AAP) in pediatric acute lymphoblastic leukemia (ALL) under the Taiwan Pediatric Oncology Group (TPOG)-ALL regimen.
The study was conducted by reviewing the chart records of 191 patients aged 1 to 18 years treated with TPOG-ALL (2002 and 2013) protocols at the National Cheng Kung University Hospital, Tainan, Taiwan, from 2002 to 2019. The disease incidence, clinical presentations, laboratory data, complications, and outcomes of AAP were investigated.
The incidence of AAP was 4.7%. The incidence was significantly higher in children treated with the TPOG-ALL-2013 (n = 62) than TPOG-ALL-2002 (n = 129) protocol (11.3% vs 1.6%, P = 0.006). Multivariate analysis identified using TPOG-ALL-2013 protocol was an independent risk factor for AAP. Pancreatic necrosis or pseudocysts developed in 7 patients (78%). Notably, 1 AAP case (11%) developed diabetes mellitus and 4 (44%) had chronic pancreatitis during a 1-year observational period. None were mortality.
The incidence of AAP was 4.7% in ALL patients treated with TPOG-ALL protocol. Although a higher cumulative dose of asparaginase in TPOG-ALL-2013 may attribute to the pancreatic toxicity, unidentified factors such as genetic predisposition or other drugs still need further study.
本研究旨在阐明台湾儿科肿瘤协作组(TPOG)-ALL 方案治疗的儿童急性淋巴细胞白血病(ALL)中,与门冬酰胺酶相关的胰腺炎(AAP)的特征和危险因素。
本研究通过回顾 2002 年至 2019 年期间,在台湾台南国立成功大学医院接受 TPOG-ALL(2002 年和 2013 年)方案治疗的 191 名 1 至 18 岁患者的图表记录进行。研究调查了 AAP 的发病情况、临床表现、实验室数据、并发症和结局。
AAP 的发病率为 4.7%。接受 TPOG-ALL-2013 方案治疗的儿童发病率明显高于接受 TPOG-ALL-2002 方案治疗的儿童(11.3% vs 1.6%,P = 0.006)。多变量分析确定使用 TPOG-ALL-2013 方案是 AAP 的独立危险因素。7 名患者(78%)发生胰腺坏死或假性囊肿。值得注意的是,1 例 AAP 患者(11%)在 1 年观察期内发生糖尿病,4 例(44%)发生慢性胰腺炎。无一例死亡。
接受 TPOG-ALL 方案治疗的 ALL 患者 AAP 的发病率为 4.7%。尽管 TPOG-ALL-2013 中的门冬酰胺酶累积剂量较高可能导致胰腺毒性,但遗传易感性或其他药物等未知因素仍需要进一步研究。